MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma

Panaccione, Alex; Zhang, Yi; Ryan, Molly; Moskaluk, Christopher A.; Anderson, Karen S.; Yarbrough, Wendell G.; Ivanov, Sergey V.

doi:10.1016/j.scr.2017.05.002

Cited by 23 publications

(20 citation statements)

References 50 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many previous studies showed that Notch1 pathway plays a crucial role in CSCs maintaining stemness. 20 – 22 Despite the opposite roles of Notch1 signaling in CD24 expression in breast cancer cells and melanoma cells, the results of both our study and So et al’s study confirmed that Notch1 signaling maintains the tumorigenic ability of CSCs.…”

Section: Discussionsupporting

confidence: 76%

Identification of CD24 as a marker for tumorigenesis of melanoma

Tang

Guo

Wang

et al. 2018

OTT

View full text Add to dashboard Cite

ObjectiveCutaneous melanoma (CM) is a common skin cancer. Surgery is still the primary treatment for CM, as melanoma is resistant to chemotherapy. In the recent years, it has been found that cancer stem-like cells (CSCs) are responsible for this drug resistance. CD24 is a widely used marker to isolate CSCs. In this study, we aimed to analyze the properties of CD24+ and CD24− subpopulation of melanoma cells.Materials and methodsWe isolated CD24+ cells CSCs using magnetic-activated cell sorting system. We extracted total RNA and carried out reverse transcription polymerase chain reaction analysis. We counted the cell colonies using soft agar assay and assessed the cell invasion using cell migration assay. We implanted CD24+ or CD24− cells into the flank of non-obese diabetic severe combined immunodeficiency mice, and measured the tumor volumes every 5 days until the end of the experiment. We carried out immunohistochemical analysis to study the tissue sections.ResultsWe demonstrated that the CD24+ subpopulation has self-renewal properties in vitro and in vivo by using soft agar assay and xenograft tumor model. Furthermore, we confirmed that CD24 expression is accompanied by activation of Notch1 signaling pathway.ConclusionThis study provides new knowledge on the role of CD24 in the tumorigenic ability of melanoma.

show abstract

Section: Discussionsupporting

confidence: 76%

Identification of CD24 as a marker for tumorigenesis of melanoma

Tang

Guo

Wang

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…SOX-10 was all positive in our series of cases. Although SOX-10 is a marker for sero-mucinous differentiation (23), our findings demonstrated that it is not a specific marker for AdCC.…”

Section: Discussioncontrasting

confidence: 69%

Myb Immunohistochemical Staining and Fluorescence in situ Hybridization in Salivary Rare Basaloid Lesions

Jie

2020

Front. Oncol.

View full text Add to dashboard Cite

Objective: Salivary rare basaloid lesions, including cribriform type basal cell adenoma (cBCA), BCA with incomplete capsule (iBCA), sialoblastoma (SB), and intercalated duct hyperplasia (IDH), could easily be misdiagnosed as adenoid cystic carcinoma (AdCC). We aim to identify an approach for differential diagnosis and to establish an optimal workflow concerning the diagnosis of these lesions. Material and methods: A panel of antibodies (MYB, β-catenin, CD117, SOX10, ki67, P63, calponin) and fluorescence in situ hybridization (FISH)-MYB were utilized to distinguish above salivary basaloid diseases from AdCC. Results: Histologically, the striking diagnostic features of cBCA, iBCA, SB, and IDH are composed of basaloid tumor cells, well-defined encapsulation, or lack of destructive invasion. Immunohistochemically, Myb immune-labeling could effectively make a distinction among cBCA, iBCA, SB, and IDH from AdCC, except in SB. cBCA and iBCA typically expressed β-catenin in the nuclei of tumor cells. There was no statistical significance in the ki67 index between SB and AdCC, but their indices were significantly higher than those of iBCA and IDH (p < 0.05, p < 0.05, respectively). P63 and calponin immune-expression were observed in the basaloid or myoepithelial cells. CD117 were observed positively in cBCA, iBCA, SB, and AdCC, except in IDH. SOX10 were observed positively in all cases. No cases had fusion of MYB and NFIB detectable by FISH, except in AdCC. Conclusion: Considering their sensitivity and specificity, FISH-Myb and an immunohistochemical panel of MYB/β-catenin/ki67 would be an optimal choice for the differential diagnosis of these basaloid lesions. Clinical relevance: Some salivary basaloid tumor or tumor-like lesions have overlapping features with AdCC. Through this present research, we suggested that the panel IHC of MYB, βcatenin, and ki67 combined with FISH-Myb should be an optimal choice for differential diagnosis among those lesions.

show abstract

“…Capturing signaling states by measuring protein phosphorylation in various cell subsets can also define or reveal their phenotype. For example, detection of WNT/β‐catenin and STAT3 signaling in a CD133 + cell line derived from a salivary adenoid cystic carcinoma by mass cytometry helped characterize these cells as cancer stem cell‐like . We recently identified novel tumor cell subsets based on basal signaling profile in glioblastoma .…”

Section: Mass Cytometry To Reveal Cancer Biology Beyond Genomicsmentioning

confidence: 99%

Beyond the message: advantages of snapshot proteomics with single‐cell mass cytometry in solid tumors

et al. 2019

View full text Add to dashboard Cite

Single‐cell technologies that can quantify features of individual cells within a tumor are critical for treatment strategies aiming to target cancer cells while sparing or activating beneficial cells. Given that key players in protein networks are often the primary targets of precision oncology strategies, it is imperative to transcend the nucleic acid message and read cellular actions in human solid tumors. Here, we review the advantages of multiplex, single‐cell mass cytometry in tissue and solid tumor investigations. Mass cytometry can quantitatively probe nearly any cellular feature or target. In discussing the ability of mass cytometry to reveal and characterize a broad spectrum of cell types, identify rare cells, and study functional behavior through protein signaling networks in millions of individual cells from a tumor, this review surveys publications of scientific advances in solid tumor biology made with the aid of mass cytometry. Advances discussed include functional identification of rare tumor and tumor‐infiltrating immune cells and dissection of cellular mechanisms of immunotherapy in solid tumors and the periphery. The review concludes by highlighting ways to incorporate single‐cell mass cytometry in solid tumor precision oncology efforts and rapidly developing cytometry techniques for quantifying cell location and sequenced nucleic acids.

show abstract

MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma

Cited by 23 publications

References 50 publications

Identification of CD24 as a marker for tumorigenesis of melanoma

Identification of CD24 as a marker for tumorigenesis of melanoma

Myb Immunohistochemical Staining and Fluorescence in situ Hybridization in Salivary Rare Basaloid Lesions

Beyond the message: advantages of snapshot proteomics with single‐cell mass cytometry in solid tumors

Contact Info

Product

Resources

About